AR061386A1 - Pirrolopiridinas sustituidas como moduladores de proteina quinasa, una composicion farmaceutica que las comprende, un proceso y un compuesto intermediario para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento del cancer. - Google Patents
Pirrolopiridinas sustituidas como moduladores de proteina quinasa, una composicion farmaceutica que las comprende, un proceso y un compuesto intermediario para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento del cancer.Info
- Publication number
- AR061386A1 AR061386A1 ARP060101646A ARP060101646A AR061386A1 AR 061386 A1 AR061386 A1 AR 061386A1 AR P060101646 A ARP060101646 A AR P060101646A AR P060101646 A ARP060101646 A AR P060101646A AR 061386 A1 AR061386 A1 AR 061386A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- general formula
- group
- preparation
- cycloalkyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- -1 SO2NH Chemical group 0.000 abstract 2
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 239000000203 mixture Chemical class 0.000 abstract 2
- 150000005255 pyrrolopyridines Chemical class 0.000 abstract 2
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 238000006069 Suzuki reaction reaction Methods 0.000 abstract 1
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000009435 amidation Effects 0.000 abstract 1
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 230000026030 halogenation Effects 0.000 abstract 1
- 238000005658 halogenation reaction Methods 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion. Preparacion de pirrolopiridinas sustituidas, a las composiciones que las contienen, a su proceso de preparacion y a su utilizacion como medicamento, en especial corno agentes anticancerígenos. Reivindicacion 1: Producto que responde a la formula (1) en la que A y Ar se seleccionan de manera independiente del grupo constituido por: arilo, heteroarilo, arilo sustituido, heteroarilo sustituido, cicloalquilo, cicloalquilo sustituido; L se selecciona del grupo constituido por: un enlace, CO, NH, CO-NH, NH-CO, NH-SO, NH-SO2, SO2NH, NH-CH2, CH2-NH, CH2-CO-NH, NH-CO-CH2, NH-CH2-CO, CO-CH2-NH, NH-CO-NH, NH-CS-NH, NH-CO-O, O-CO-NH; uno de Y y Z se elige entre N y NO, y el otro de Y y Z es C(R5), y W es C(R6); R1, R5, y R6 se seleccionan cada uno de manera independiente del grupo constituido por: H, halogeno, R2, CN, O(R2), OC(O)(R2), OC(O)N(R2)(R3), OS(O2)(R2), N(R2)(R3), N=C(R2)(R3), N(R2)C(O)(R3), N(R2)C(O)O(R3), N(R4)C(O)N(R2)(R3), N(R4)C(S)N(R2)(R3), N(R2)S(O2)(R3), C(O)(R2), C(O)O(R2), C(O)N(R2)(R3), C(=N(R3))(R2), C(=N(OR3))(R2), S(R2), S(O)(R2), S(O2)(R2), S(O2)O(R2), S(O2)N(R2)(R3); en el que cada R2, R3, R4 se selecciona de manera independiente del grupo constituido por H, alquilo, alquileno, alquinilo, arilo, heteroarilo, cicloalquilo, heterociclilo, alquilo sustituido, alquileno sustituido, alquinilo sustituido, arilo sustituido, heteroarilo sustituido, cicloalquilo sustituido, heterociclilo sustituido, alquileno, alquileno sustituido, alquinilo sustituido; en el que, cuando R2 y R3 están presentes simultáneamente en uno de R1, R5 y R6, se pueden unir entre sí para formar un ciclo; Ra se selecciona del grupo constituido por H, alquilo C1-4, cicloalquilo C3-4. Reivindicacion 32: Procedimiento de preparacion de productos de formula general (1) tal como se definen en la reivindicacion 1, caracterizado por que un producto de formula general (5) sufre las etapas siguientes: a) halogenacion en posicion 3, a continuacion, b) acoplamiento de Suzuki en posicion 3, para obtener un producto de formula general (3), c) amidacion del éster en posicion 2, para obtener un producto de formula general (2), d) acilacion del grupo amino-fenilo en posicion 3. Reivindicacion 33: A título de productos intermedios, los compuestos de formula general (2) en la que R1, Ra, Z, Y, W son tal como se definen anteriormente, para la preparacion de productos de formula general (1) tales como se definen en la reivindicacion 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0504173A FR2884821B1 (fr) | 2005-04-26 | 2005-04-26 | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061386A1 true AR061386A1 (es) | 2008-08-27 |
Family
ID=35517344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101646A AR061386A1 (es) | 2005-04-26 | 2006-04-25 | Pirrolopiridinas sustituidas como moduladores de proteina quinasa, una composicion farmaceutica que las comprende, un proceso y un compuesto intermediario para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento del cancer. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7947706B2 (es) |
| EP (1) | EP1877409B1 (es) |
| JP (1) | JP2008539211A (es) |
| KR (1) | KR20080007229A (es) |
| CN (1) | CN101166739A (es) |
| AR (1) | AR061386A1 (es) |
| AT (1) | ATE433976T1 (es) |
| AU (1) | AU2006239105A1 (es) |
| BR (1) | BRPI0613161A2 (es) |
| CA (1) | CA2605744A1 (es) |
| CR (1) | CR9463A (es) |
| CY (1) | CY1109369T1 (es) |
| DE (1) | DE602006007337D1 (es) |
| DK (1) | DK1877409T3 (es) |
| DO (1) | DOP2006000096A (es) |
| EA (1) | EA012983B1 (es) |
| ES (1) | ES2328629T3 (es) |
| FR (1) | FR2884821B1 (es) |
| GT (1) | GT200600174A (es) |
| HR (1) | HRP20090494T1 (es) |
| IL (1) | IL186523A0 (es) |
| MA (1) | MA29480B1 (es) |
| MX (1) | MX2007013084A (es) |
| NO (1) | NO20075918L (es) |
| PA (1) | PA8671301A1 (es) |
| PE (1) | PE20071420A1 (es) |
| PL (1) | PL1877409T3 (es) |
| PT (1) | PT1877409E (es) |
| RS (1) | RS51136B (es) |
| SI (1) | SI1877409T1 (es) |
| TN (1) | TNSN07360A1 (es) |
| TW (1) | TW200718701A (es) |
| WO (1) | WO2006114520A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EA200970361A1 (ru) | 2006-10-09 | 2010-02-26 | Такеда Фармасьютикал Компани Лимитед | Ингибиторы киназы |
| EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| MX2009006706A (es) * | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. |
| CA2672213C (en) | 2006-12-22 | 2016-02-16 | Astex Therapeutics Limited | Bicyclic amine derivatives as protein tyrosine kinase inhibitors |
| AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| BRPI1008709B8 (pt) | 2009-04-03 | 2021-05-25 | Hoffmann La Roche | dispersão sólida, formulação, composição e comprimido compreendendo {3-[5-(4-cloro-fenil)-1h-pirrol[2,3-b]piridina-3-carbonil]-2,4-diflúor-fenil}-amida do ácido propano-1-sulfônico |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| US20110030037A1 (en) * | 2009-07-07 | 2011-02-03 | Vadim Olshansky | Zone migration in network access |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| US20110112127A1 (en) | 2009-11-06 | 2011-05-12 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MY162950A (en) | 2011-02-07 | 2017-07-31 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| WO2013181075A1 (en) * | 2012-05-29 | 2013-12-05 | Merck Sharp & Dohme Corp. | Isotopically labeled biaryl urea compounds |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| GB201310464D0 (en) * | 2013-06-12 | 2013-07-24 | Lytix Biopharma As | Compounds |
| GB201310460D0 (en) * | 2013-06-12 | 2013-07-24 | Lytix Biopharma As | Compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3254843B2 (ja) * | 1993-08-09 | 2002-02-12 | 三菱ウェルファーマ株式会社 | 新規縮合ヘテロ環誘導体 |
| US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US7427623B2 (en) * | 2001-09-11 | 2008-09-23 | Smithkline Beecham Corporation | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof |
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| MXPA04003758A (es) * | 2001-10-22 | 2005-06-20 | Univ New York State Res Found | Inhibidores de proteina - cinasas y proteina-fosfatasas, metodos para disenarlos y metodos para usarlos. |
| DE60316542T2 (de) * | 2002-03-28 | 2008-07-03 | Eisai R&D Management Co., Ltd. | 7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen |
| FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
-
2005
- 2005-04-26 FR FR0504173A patent/FR2884821B1/fr not_active Expired - Fee Related
-
2006
- 2006-04-25 PE PE2006000435A patent/PE20071420A1/es not_active Application Discontinuation
- 2006-04-25 AR ARP060101646A patent/AR061386A1/es unknown
- 2006-04-26 BR BRPI0613161-1A patent/BRPI0613161A2/pt not_active IP Right Cessation
- 2006-04-26 AT AT06743743T patent/ATE433976T1/de active
- 2006-04-26 DE DE602006007337T patent/DE602006007337D1/de active Active
- 2006-04-26 ES ES06743743T patent/ES2328629T3/es active Active
- 2006-04-26 PL PL06743743T patent/PL1877409T3/pl unknown
- 2006-04-26 RS RSP-2009/0400A patent/RS51136B/sr unknown
- 2006-04-26 DK DK06743743T patent/DK1877409T3/da active
- 2006-04-26 TW TW095114907A patent/TW200718701A/zh unknown
- 2006-04-26 CA CA002605744A patent/CA2605744A1/fr not_active Abandoned
- 2006-04-26 EP EP06743743A patent/EP1877409B1/fr active Active
- 2006-04-26 CN CNA200680014034XA patent/CN101166739A/zh active Pending
- 2006-04-26 HR HR20090494T patent/HRP20090494T1/hr unknown
- 2006-04-26 DO DO2006000096A patent/DOP2006000096A/es unknown
- 2006-04-26 KR KR1020077024847A patent/KR20080007229A/ko not_active Withdrawn
- 2006-04-26 GT GT200600174A patent/GT200600174A/es unknown
- 2006-04-26 AU AU2006239105A patent/AU2006239105A1/en not_active Withdrawn
- 2006-04-26 WO PCT/FR2006/000925 patent/WO2006114520A2/fr not_active Ceased
- 2006-04-26 MX MX2007013084A patent/MX2007013084A/es active IP Right Grant
- 2006-04-26 SI SI200630396T patent/SI1877409T1/sl unknown
- 2006-04-26 PA PA20068671301A patent/PA8671301A1/es unknown
- 2006-04-26 PT PT06743743T patent/PT1877409E/pt unknown
- 2006-04-26 EA EA200702329A patent/EA012983B1/ru not_active IP Right Cessation
- 2006-04-26 JP JP2008508258A patent/JP2008539211A/ja active Pending
-
2007
- 2007-09-21 TN TNP2007000360A patent/TNSN07360A1/en unknown
- 2007-10-09 IL IL186523A patent/IL186523A0/en unknown
- 2007-10-11 US US11/870,640 patent/US7947706B2/en not_active Expired - Fee Related
- 2007-10-22 CR CR9463A patent/CR9463A/es not_active Application Discontinuation
- 2007-11-16 NO NO20075918A patent/NO20075918L/no not_active Application Discontinuation
- 2007-11-22 MA MA30412A patent/MA29480B1/fr unknown
-
2009
- 2009-09-16 CY CY20091100957T patent/CY1109369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061386A1 (es) | Pirrolopiridinas sustituidas como moduladores de proteina quinasa, una composicion farmaceutica que las comprende, un proceso y un compuesto intermediario para su preparacion y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| AR052357A1 (es) | Pirazolo piridinas sustituidas moduladoras de la actividad de quinasas | |
| AR077999A1 (es) | Antagonistas de pirimidin y triazin-hepcidina | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR082699A1 (es) | Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto | |
| CL2009001554A1 (es) | Compuestos derivados de 4-(sulfonilaminoalquilamino)-n-fenil-n'-hidroxi-1,2,5-oxadiazol-3-carboximidamida; formas cristalinas; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades tales como cancer, infeccion viral, depresion, entre otras. | |
| JP2016513737A5 (es) | ||
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| UY29384A1 (es) | Derivados del ácido2-3s,4r)-4-(((3,4-dicloro-5-metil-1h-pirrol-2-il) carbonil)amino)-1,3-tiazol-5-carboxílico y sus sales, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciónes. | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| EA201890236A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| JP2016053042A5 (es) | ||
| AR033678A1 (es) | Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| CL2017002022A1 (es) | Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina | |
| AR057131A1 (es) | Derivados de purina como inmunomodulador | |
| GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
| DOP2010000103A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas quinasas b | |
| RU2013139353A (ru) | Трициклические пирролопроизводные, способ их получения и их применение в качестве ингибиторов киназы | |
| PE20171341A1 (es) | Compuestos de pirazina para el tratamiento de enfermedades infecciosas | |
| MX2022011354A (es) | Compuestos de pirimidina fusionados como moduladores de kcc2. | |
| AR045387A1 (es) | Compuestos bencimidazolil n-sustituidos inhibidores de c-kit; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de un trastorno proliferativo | |
| UY30547A1 (es) | Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones. | |
| BR112015014222A2 (pt) | composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |